Linhui Huo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linhui Huo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Conxita Jacobs-Cachá
Clinical Biochemistry, Drug Delivery and Therapy Research Group, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain
1 shared publication - Frederic Pons-Pellicer
Nephrology and Transplantation Research Group, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain
1 shared publication - Irene Martínez-Díaz
Nephrology and Transplantation Research Group, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain
1 shared publication - Jordi Vilardell-Vilà
Nephrology and Transplantation Research Group, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain
1 shared publication - María José Soler
Department of Nephrology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain
1 shared publication - Sara Núñez-Delgado
Centro de Referencia CSUR para Patología Glomerular Compleja, Servei de Nefrologia, Vall d’Hebron Hospital Universitari, 08035 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 111
The Apelinergic System in Kidney Disease: Novel Perspectives
Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications.
- 22 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (1) , 111
Open AccessThe Apelinergic System in Kidney Disease: Novel Perspectives
Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications.